Human and mouse long noncoding RNAs reengineered for exogenous delivery reduce LPS-induced inflammation in human macrophages and mice - PubMed
a day ago
- #gene therapy
- #lncRNA
- #inflammation
- Long noncoding RNAs (lncRNAs) are reengineered for exogenous delivery to treat acute inflammation.
- Three lncRNAs—GAPLINC, MIST, and DRAIR—were optimized for specificity and performance in reducing LPS-induced inflammation.
- Each lncRNA targets distinct cytokines: GAPLINC reduces IL-1β, DRAIR reduces IL-6, and MIST attenuates TNFα posttranscriptionally.
- A lipid nanoparticle delivery system was optimized for in vivo use without confounding effects.
- Reengineered GAPLINC showed potential for clinical application by reducing inflammation in human monocytes.